

of mammalian cell in vivo or ex vivo.

92 ~~23~~. (Amended) [The antibody of claim ~~2~~³, wherein said] A monoclonal antibody which (a) binds to a soluble extracellular domain sequence of an Apo-2 polypeptide which [comprises] consists of amino acids 1 to 182 of SEQ ID NO:1 and (b) stimulates apoptosis in at least one type of mammalian cell in vivo or ex vivo.

Sub D ~~24~~. (Amended) A monoclonal antibody which binds to a soluble polypeptide [comprising] which is (a) an extracellular domain sequence of [a native sequence] Apo-2 polypeptide which [comprises] consists of amino acids 54 to 182 of SEQ ID NO:1 or (b) a fragment of (a) which binds Apo-2 ligand, is immunogenic, or is capable of modulating apoptosis in a mammalian cell.

C1 ~~19~~ ~~25~~. (Amended) The monoclonal antibody of claim ~~21~~¹ or ~~24~~¹⁴, wherein said antibody is a chimeric antibody.

20 ~~26~~. (Amended) The monoclonal antibody of claim ~~21~~¹ or ~~24~~¹⁴, wherein said antibody is a humanized antibody.

Sub E1 ~~27~~ ~~28~~. (Amended) A homodimeric molecule comprising any two antibodies of claims ~~8~~²¹, ~~10~~²³, [19,] ~~21~~¹, ~~22~~³ or ~~24~~¹⁴.

2 ~~29~~. Please add the following claims:

~~30~~. The monoclonal antibody of claim ~~21~~¹ which is a human antibody.

5 ~~31~~. The monoclonal antibody of claim ~~22~~⁴ which is a human antibody.

C3 ~~32~~. The monoclonal antibody of claim ~~23~~⁹ which is a human antibody.

16 ~~33~~. The monoclonal antibody of claim ~~24~~¹⁴ which is a human antibody.

6 ~~34~~. The monoclonal antibody of claim ~~25~~⁴ which is a chimeric antibody.